Pharma firms spend $130M lobbying on TrumpRx plan, while Novo Nordisk reports 27.7% weight loss in high‑dose Wegovy trial

Seventeen pharmaceutical companies that back the White House’s TrumpRx prescription‑drug pricing program collectively spent more than $130 million on federal lobbying in 2025. That represents a roughly 23% increase from the previous year and outpaced lobbying growth across the broader industry, according to OpenSecrets data.

In a separate development, Novo Nordisk said that participants receiving a higher‑dose version of its Wegovy obesity injection lost an average of 27.7% of their body weight in a recent trial. The result highlights the drug’s potential for substantial weight reduction in a subset of patients.

Both stories illustrate the dual focus of the sector: intense policy engagement as pricing reforms take shape, and ongoing clinical advances that could expand treatment options for obesity.